Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 22, 2025 • 2:41 PM ET

Date/Time Source News Release
08/30/2017 06:00 PM EDT PR Newswire Australian cancer specialists may hold key to next advancement in ovarian cancer treatment
08/22/2017 12:06 AM EDT PR Newswire GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
08/13/2017 11:02 PM EDT PR Newswire Board Review of Business Operations and Governance
08/06/2017 11:03 PM EDT PR Newswire Progress Update on Cantrixil(TM) (TRXE-002-1) Development
03/09/2017 08:21 PM EST PR Newswire Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure
03/06/2017 04:32 AM EST PR Newswire Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program
09/14/2016 07:00 AM EDT PR Newswire Conversion of Convertible Notes
08/11/2016 01:59 AM EDT PR Newswire Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
05/01/2016 10:43 PM EDT PR Newswire Novogen Provides Update On Development Of Cantrixil
02/19/2016 01:18 AM EST PR Newswire Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant
Page
  • 1
  • 2